Premarket Decliner
APVO Aptevo Therapeutics5.13+2.31+81.9%
Premarket:4.45-0.68 (-13.3%)
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
ACCESS NewswireFri, 20-Jun 8:55 AM
